Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
A new version of an AI-enabled mammography software may enhance breast cancer detection and bolster workflow efficiency for mammography assessment.
Therapixel’s updated MammoScreen suite has garnered new 510(k) clearances for breast density evaluation and new software that offers a variety of features to help reduce workflow bottlenecks for radiologists.
The company said key features include the ability to organize the day’s worklist through a case complexity index; an algorithm that facilitates assessment of 2D and 3D breast imaging and a patient’s prior history; and automated pre-reporting that facilitates enhanced efficiency with reporting of mammography findings.
“With these new features, radiologists can double their reading time savings compared to the previous version. Radiologists will appreciate the reduced fatigue, administrators the improved efficiency and care consistency, and the IT team the seamless one-time installation. We’re proud to launch this new version of MammoScreen, once again delivering unparalleled value to radiologists and patients,” noted Matthieu Leclerc-Chalvet, the chief executive officer of Therapixel.
Multicenter Study Identifies Key Factors Associated with Mammogram-Occult Ipsilateral Breast Cancer
October 9th 2024A symptomatic first breast cancer diagnosis, prevailing breast density at a second breast cancer diagnosis and trabecular thickening on surveillance mammography were linked to mammogram-occult ipsilateral breast cancer, according to new research.
Radiology Experience, Breast Density and Screening Mammography: What New Research Reveals
October 4th 2024In a study looking at the impact of experience and case volume of breast screening radiologists, researchers found that reviewing more than 150 cases per week was necessary to achieve an 80 percent rate of true-positive assessments for malignant calcifications.